Hypogonadotropic hypogonadism 13 with or without anosmia is a rare genetic condition that affects sexual development and sometimes smell. People with this condition often have delayed or absent puberty, low sex hormone levels, and possible reduced fertility. Some have a normal sense of smell, while others have partial or complete loss of smell, and early symptoms of hypogonadotropic hypogonadism 13 can include absent periods or no testicular growth in the teen years. It is lifelong, usually recognized in adolescence or young adulthood, and management focuses on hormone replacement and fertility treatments. The outlook varies, but many people live long and full lives with appropriate care.
Overview
Hypogonadotropic hypogonadism 13 with or without anosmiaSymptoms
Hypogonadotropic hypogonadism 13 with or without anosmia features delayed or absent puberty and infertility. Early signs include reduced or absent smell, undescended testes or small penis in boys, and missed periods or limited breast growth in girls.
Outlook and prognosis
Many living with hypogonadotropic hypogonadism 13 with or without anosmia improve with tailored hormone therapy, often restoring puberty, sexual function, bone health, and fertility. Response can vary, so ongoing monitoring matters. Early symptoms of hypogonadotropic hypogonadism 13 benefit from early evaluation.
Causes and risk factors
Hypogonadotropic hypogonadism 13 with or without anosmia usually stems from a change in a single gene, inherited in some families or appearing new. Risk increases with affected parent and parental relatedness. Environment may influence severity but does not cause it.
Genetic influences
Genetics play a central role in hypogonadotropic hypogonadism 13 with or without anosmia. Variants in the CHD7 gene commonly cause it, and inheritance is usually autosomal dominant, sometimes de novo. Testing helps confirm diagnosis, guide family planning, and inform counseling.
Diagnosis
Doctors look for delayed or absent puberty with low gonadotropins and sex hormones. Reduced smell may be present. Hormone tests, smell testing, MRI, and genetic tests confirm the genetic diagnosis of Hypogonadotropic hypogonadism 13 with or without anosmia.
Treatment and drugs
Treatment for hypogonadotropic hypogonadism 13 with or without anosmia focuses on restoring hormones, protecting bones, and supporting fertility goals. Many start hormone replacement (estrogen/progestin or testosterone); some use gonadotropins or pulsatile GnRH to trigger puberty and fertility. Regular follow-up tracks growth, bone density, mood, and metabolic health.
Symptoms
People with hypogonadotropic hypogonadism 13 with or without anosmia typically notice that puberty doesn’t start or doesn’t fully progress. Early on, this might look like being much later than peers to develop periods, breast growth, facial hair, or a deeper voice. Many families wonder about early features of hypogonadotropic hypogonadism 13 with or without anosmia, such as a lack of puberty changes by the early to mid-teen years. Some also have a reduced sense of smell, while others have normal smell.
Puberty starts late or doesn’t progress as expected. This delay is a hallmark of hypogonadotropic hypogonadism 13 with or without anosmia.
Girls and women may not get their first period. This is common in hypogonadotropic hypogonadism 13 with or without anosmia until hormones are replaced.
Breast growth may be minimal or flat. Bra size may not change through the teen years without treatment.
Underarm and pubic hair may be limited. Facial hair may be light, and acne can be less noticeable than peers.
How people usually first notice Hypogonadotropic hypogonadism 13 with or without anosmia?
Many families first notice something is different around puberty, when periods don’t start on time or at all, or when testicles don’t enlarge and facial or body hair stays sparse compared with peers. In infancy or childhood, some clues can appear earlier, such as undescended testicles, a small penis in newborn boys, poor growth of the sense of smell (anosmia) or a child who doesn’t react to strong odors, and sometimes subtle facial or midline features a doctor points out. Doctors usually confirm the “first signs of hypogonadotropic hypogonadism 13 with or without anosmia” with hormone testing and, when smell is affected, simple smell checks or an MRI to look at the smell pathways.
Types of Hypogonadotropic hypogonadism 13 with or without anosmia
People living with hypogonadotropic hypogonadism 13 often notice changes tied to puberty timing, fertility, and sense of smell in daily life—like delayed periods or testicular growth, low energy, or trouble detecting odors while cooking. This condition is genetic and has recognized clinical variants that differ mainly by whether smell is affected and how strongly the reproductive hormone signal is reduced. Clinicians often describe them in these categories: anosmic (with reduced or absent smell), normosmic (normal smell), and, less commonly, milder or variable forms that may present later. Not everyone will experience every type, and the balance of symptoms can shift over time.
Anosmic variant
Smell is reduced or absent, which can show up as not sensing fragrances, food aromas, or warning odors like smoke. Puberty is delayed or incomplete, and fertility is usually reduced without treatment.
Normosmic variant
Smell remains normal in daily life tests, like noticing coffee or perfume, but the reproductive hormone signal is still low. Puberty and fertility are affected similarly, though some features may be milder.
Variable severity
Symptoms can be milder, fluctuate, or appear later, sometimes first noticed as irregular periods or low libido in young adulthood. Early symptoms of hypogonadotropic hypogonadism 13 may be subtle, and fertility issues may be the first clue.
Family-linked patterns
Some families show a consistent pattern—mostly anosmic or mostly normosmic—while others have a mix among relatives. These variants of hypogonadotropic hypogonadism 13 reflect differences in how the same gene change affects smell pathways and hormone signaling.
What genetics can tell you about symptoms
Some people with variants in the GNRHR gene develop delayed or absent puberty, low sex hormone levels, and fertility challenges; some also have reduced or absent smell (anosmia). These changes happen because the gene variants disrupt signals from the brain that trigger hormone release.
Causes and risk factors
Hypogonadotropic hypogonadism 13 with or without anosmia is caused by a gene change that disrupts brain signals that start puberty and support fertility. The change may be passed down from a parent, or it may occur as a new mutation. Risk factors for hypogonadotropic hypogonadism 13 with or without anosmia include a family history of the condition. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Nutrition, major weight loss, intense training, long illness, or high stress do not cause it but can delay puberty and may make features more noticeable.
Environmental and biological risk factors
Environmental and biological risk factors for Hypogonadotropic hypogonadism 13 with or without anosmia are not fully mapped because this condition often begins before birth. Doctors often group risks into internal (biological) and external (environmental). Below are factors that may raise the chance of HH13 occurring, separate from how it behaves over time. Evidence is strongest for internal factors; environmental links are more general to fetal brain development.
Conception at older paternal ages is linked to a higher chance of new changes arising at conception. This can slightly increase the likelihood of rare conditions such as Hypogonadotropic hypogonadism 13 with or without anosmia. The overall chance for any one condition remains small.
Pregnancy at older maternal ages carries a higher baseline risk of congenital differences, including those that affect brain and hormone development. While not specific to HH13, it may modestly raise the background risk. Most pregnancies at older ages are healthy.
HH13 is identified more often in males. Differences in how puberty looks externally make it easier to spot, which increases observed risk. The underlying biology may also play a role.
Significant exposure to high-dose ionizing radiation or heavy metals such as lead or mercury early in pregnancy can disrupt fetal brain and smell pathway development. This could raise the chance of differences in the hormone signals that start puberty. Such exposures are uncommon in most daily settings.
Genetic risk factors
Hypogonadotropic hypogonadism 13 with or without anosmia is driven by changes in a single gene that affects the brain’s signal to start and maintain puberty, and sometimes the sense of smell. These changes can be inherited within a family or arise for the first time in a child. Carrying a genetic change doesn’t guarantee the condition will appear. Understanding the gene behind Hypogonadotropic hypogonadism 13 also helps explain why early symptoms of Hypogonadotropic hypogonadism 13 can vary widely between people.
Key gene variant: A change in one specific gene underlies Hypogonadotropic hypogonadism 13 by weakening the brain’s signal to start and maintain puberty. The same change can also influence nerves linked to smell, which is why anosmia may or may not appear.
GnRH signal defect: The altered gene impairs the rhythmic release of the brain’s puberty hormone signal (GnRH) that tells the pituitary to switch on the ovaries or testes. With fewer or weaker signals, the sex glands remain underactive.
Inheritance patterns: Reported families show autosomal patterns, meaning the gene sits on a non‑sex chromosome. Some families follow an autosomal recessive carrier pattern, while others show a single‑copy effect with variable expression. Genetic counseling can help clarify which pattern applies in your family.
Incomplete penetrance: Not everyone with the same variant develops the full picture of Hypogonadotropic hypogonadism 13. Some have very mild hormone changes, while others have more pronounced effects.
Anosmia spectrum: Smell can be normal, reduced, or absent in people with Hypogonadotropic hypogonadism 13. Differences can occur even between siblings with the same variant.
Compound heterozygosity: Some with autosomal recessive disease carry two different changes in the same gene, one inherited from each parent. Each change weakens gene function; together they cause the condition.
Oligogenic modifiers: Additional changes in other puberty or smell genes can modify who is affected and how severe the features are. This helps explain variation in age at diagnosis or smell.
De novo variant: In some, the gene change arises for the first time and is not found in either parent. If present in all cells, it can be passed to children.
Consanguinity risk: Parents who are blood relatives are more likely to carry the same rare variant. This raises the chance of autosomal recessive Hypogonadotropic hypogonadism 13 in their children.
Family history: Relatives with delayed puberty, infertility, or smell loss can signal inherited risk for Hypogonadotropic hypogonadism 13. Sharing this history guides which genetic tests to order.
Lifestyle risk factors
Hypogonadotropic hypogonadism 13 with or without anosmia is a genetic condition; lifestyle habits do not cause it, but they can influence symptoms, treatment response, and long-term complications. There are no lifestyle risk factors for Hypogonadotropic hypogonadism 13 with or without anosmia, yet daily choices can affect bone health, energy, sexual function, and fertility care success. The points below focus on how lifestyle affects Hypogonadotropic hypogonadism 13 with or without anosmia in practical ways. Discuss any changes with your clinical team to align with your treatment plan.
Taking prescribed sex-steroid or gonadotropin therapy as directed helps develop/maintain sexual characteristics, bone density, and wellbeing. Skipping doses can worsen fatigue, mood, and bone loss and delay fertility planning in HH13.
Adequate calcium, vitamin D, and protein intake supports bone mineralization when sex hormones are low. Poor intake raises osteoporosis and fracture risk in hypogonadism.
Regular resistance and impact exercise helps build or preserve bone density and muscle despite low sex steroids. Sedentary habits accelerate bone loss and metabolic risk in HH13.
Severe undernutrition and extreme dieting can further suppress reproductive signaling and complicate hormone dosing. Obesity can alter hormone metabolism, reduce fertility treatment success, and increase dosing needs.
Risk prevention
Hypogonadotropic hypogonadism 13 with or without anosmia is a genetic condition, so you can’t prevent the condition itself, but you can lower the risk of complications. Prevention isn’t about perfection, it’s about small steps that add up. Acting early—especially when early symptoms of hypogonadotropic hypogonadism 13 include delayed or absent puberty—can protect bone health, mood, and future fertility. Regular care and practical home safety steps also help if smell is reduced or absent.
Early diagnosis and ongoing follow-up help prevent avoidable problems from hypogonadotropic hypogonadism 13. Lab checks and growth/sexual development tracking let your team adjust treatment before issues build.
Starting puberty induction or hormone replacement on time supports bones, heart health, and mood. Staying on the prescribed dose lowers fracture risk and helps energy and blood counts.
Weight-bearing exercise and enough calcium and vitamin D support stronger bones in hypogonadotropic hypogonadism 13. Doctors may recommend bone density scans and adjust hormones to protect long-term bone strength.
Balanced eating and regular activity can improve cholesterol, blood pressure, and insulin response. This helps offset metabolic risks linked to low sex hormone levels.
Transmission
Hypogonadotropic hypogonadism 13 with or without anosmia is a genetic condition, not an infection, so it cannot be “caught” or spread through everyday contact, coughing, sex, or blood exposure. The genetic transmission of Hypogonadotropic hypogonadism 13 with or without anosmia happens when a child inherits a gene change from a parent; in reported families, it may be passed down by one affected parent or by two carrier parents, and it can also appear for the first time as a new change (de novo). Because features can vary—even within the same family—some relatives may have a reduced sense of smell or delayed puberty while others have few or no symptoms. If a parent carries the gene change, each pregnancy carries a chance of passing it on; a genetics professional can explain how Hypogonadotropic hypogonadism 13 with or without anosmia is inherited in your family.
When to test your genes
This is a genetic condition, so consider testing if puberty is delayed, fertility is unexplained, or smell is reduced or absent—especially with a family history. Test sooner if planning pregnancy or needing tailored hormone therapy, as results can guide timing, dosing, and monitoring. A genetics professional can help choose the right panel and interpret results.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like keeping up with peers during puberty or noticing reduced sense of smell. Getting a diagnosis is often a turning point toward answers and support. Doctors look for a pattern of delayed or absent puberty, low sex hormone levels, and a weaker sense of smell, then confirm with targeted tests. Understanding how the diagnosis of Hypogonadotropic hypogonadism 13 with or without anosmia is made can also guide treatment and family planning.
Doctors review growth, timing of puberty, smell changes, and any fertility concerns. A focused physical exam looks for features like smaller testes or ovaries and limited pubertal development. Findings help decide which tests to run next.
Blood tests measure luteinizing hormone, follicle-stimulating hormone, and sex hormones like estradiol or testosterone. In this condition, these are typically low or inappropriately normal for the stage of puberty. Results support a central (brain-based) cause.
Simple smell identification tests check for reduced or absent sense of smell. Anosmia supports a form linked to Kallmann spectrum, while a normal sense of smell points to a normosmic form. Either pattern can occur in Hypogonadotropic hypogonadism 13 with or without anosmia.
Doctors may perform hormone stimulation tests, such as giving GnRH or related medicines, to see how the pituitary responds. A blunted response supports a diagnosis of central hypogonadism. This helps distinguish it from gland problems in the testes or ovaries.
Stages of Hypogonadotropic hypogonadism 13 with or without anosmia
Hypogonadotropic hypogonadism 13 with or without anosmia does not have defined progression stages. It typically shows up when puberty doesn’t start or stalls, and while features can vary from person to person, the condition itself doesn’t follow a step-by-step worsening pattern. Different tests may be suggested to help confirm the diagnosis, including hormone blood tests, smell testing, a brain MRI to look at the pituitary region, and sometimes genetic testing. Clinicians also consider early symptoms of hypogonadotropic hypogonadism 13 with or without anosmia—like delayed or absent puberty—and track response to treatment over time.
Outlook and prognosis
Looking ahead can feel daunting, but most people with Hypogonadotropic hypogonadism 13 with or without anosmia do well once the condition is recognized and treated. Lifelong hormone replacement is usually needed to support puberty, bone strength, sexual health, and energy. For many, this also restores fertility with the help of targeted hormone therapy or assisted reproduction. Early care can make a real difference in preventing complications such as low bone density or mood changes.
Doctors call this the prognosis—a medical word for likely outcomes. Without treatment, hypogonadism can lead to reduced muscle mass, osteoporosis, and challenges with fertility. With treatment started in the teen years or adulthood, day‑to‑day life often becomes stable, and early symptoms of Hypogonadotropic hypogonadism 13 with or without anosmia tend to ease. Mortality is not increased by the condition itself; risks mainly relate to long‑term low hormones and are manageable with routine care.
Everyone’s journey looks a little different. Some people regain a sense of smell over time, while others never develop it; this difference doesn’t usually change overall health or life expectancy. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including nutrition, exercise, and staying on prescribed hormones. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Hypogonadotropic hypogonadism 13 with or without anosmia usually involves a lifelong difference in how the brain signals the ovaries or testes, which can shape puberty, fertility, bone health, and sense of smell. Long-term effects vary widely, and two people in the same family can have very different experiences. Many have a typical life span, though the condition can lead to ongoing health needs related to sex hormones and bone strength. Some adults experience partial or full recovery of hormone signaling over time, but this is not predictable.
Delayed or absent puberty is often among the early symptoms of hypogonadotropic hypogonadism and can affect the teen growth spurt. This may lead to shorter adult height and a more childlike body shape without typical pubertal changes.
Many have reduced or absent spontaneous fertility due to low signals from the brain to the ovaries or testes. Some experience natural recovery later in life, which can allow conception without medical help.
Low sex hormone levels can reduce bone mineral density, increasing the risk of osteopenia or osteoporosis and fractures. These bone effects can accumulate over years if hormone levels stay low.
People may notice low sex drive, reduced arousal, or less sexual satisfaction. Some men have erectile difficulties, and some women have vaginal dryness or discomfort with intercourse.
How is it to live with Hypogonadotropic hypogonadism 13 with or without anosmia?
Living with hypogonadotropic hypogonadism 13 with or without anosmia often means navigating delayed or absent puberty, low energy, reduced libido, and challenges with fertility, alongside the practical frustrations of medical appointments and hormone treatments. For some, an impaired or absent sense of smell adds safety considerations and small daily inconveniences, like not detecting smoke or spoiled food, that can quietly wear on confidence. Partners, family, and friends may notice mood changes, shifts in intimacy, or the time and planning needed for therapy, but clear communication and support make a real difference. Many people find that with consistent care, realistic goals, and a care team that listens, daily life becomes more predictable and fulfilling.
Treatment and drugs
Treatment for Hypogonadotropic hypogonadism 13 with or without anosmia focuses on replacing the hormones the body isn’t making and, when desired, helping with fertility. For many, this means daily or periodic sex hormone therapy—testosterone for males, and estrogen with progesterone for females—to support puberty, bone health, sexual function, and overall well-being. When fertility is a goal, doctors may use gonadotropins (hCG and FSH) or pulsatile GnRH to stimulate the ovaries or testes; these options can help many people achieve pregnancy but typically require close monitoring. Alongside medical treatment, lifestyle choices play a role, including calcium and vitamin D for bones, weight-bearing exercise, and regular checkups to adjust doses and track side effects. If you’re unsure, write down questions to bring to your next visit.
Non-drug treatment
Living with Hypogonadotropic hypogonadism 13 with or without anosmia often involves more than prescriptions—day-to-day supports can protect bone health, sexual wellbeing, mood, and safety. Beyond prescriptions, supportive therapies can make a meaningful difference alongside medical care. These approaches can help you stay active, plan for fertility, and adjust to reduced or absent sense of smell. Care plans vary by age and goals, and your team can tailor them over time.
A genetics professional can explain inheritance, testing options for relatives, and what results mean. This helps with family planning and understanding long-term health considerations.
Counseling can address anxiety, low mood, or body-image concerns that may accompany delayed puberty or infertility. Therapists familiar with endocrine conditions can teach coping skills and support partners and families.
A clinician or sex therapist can guide comfort, desire, and intimacy concerns linked to hormonal changes. Practical tips, pelvic floor strategies, and communication skills can improve sexual satisfaction.
Regular weight-bearing and resistance activity helps maintain bone density when hormones are low. Start gradually and build a mixed routine that fits your fitness level to lower fracture risk.
Your genes may have an impact on how drugs work for you
Genes that affect hormone signaling, receptors, and drug‑processing enzymes can change how people with hypogonadotropic hypogonadism 13 respond to therapies like GnRH, gonadotropins, or sex steroids. This can alter dose needs, timing of response, side effects, and fertility outcomes.
Pharmacological treatments
Treatment for hypogonadotropic hypogonadism 13 focuses on replacing missing hormones to support puberty, sexual health, fertility, and bone strength. Many living with this condition notice day‑to‑day changes—like low energy, delayed puberty, or trouble with sex—that improve once hormones are balanced; these can be early symptoms of hypogonadotropic hypogonadism 13. Plans differ for men and women and can be short‑term for puberty induction or long‑term for maintenance and fertility. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy).
Testosterone cypionate or enanthate injections, or testosterone undecanoate, can restore levels in men. Transdermal options like testosterone gel or patch are alternatives for steadier daily dosing. This helps energy, libido, erections, muscle, and bone.
17β‑estradiol (patch, gel, or pill) is used to induce and maintain puberty and menstrual cycles in women. A progestin such as micronized progesterone or medroxyprogesterone is added to protect the uterus. Doses are increased gradually to mimic natural development.
Human chorionic gonadotropin (hCG) injections stimulate testosterone production in the testes. Recombinant follicle‑stimulating hormone (FSH; follitropin alfa or beta) or menotropins (hMG) are added to promote sperm production. Treatment is continued for months to achieve fertility.
Recombinant FSH or menotropins help grow ovarian follicles in women seeking pregnancy. An hCG “trigger” injection supports final egg maturation and ovulation. Ultrasound and blood tests guide dosing for safety and success.
Genetic influences
People often ask whether Hypogonadotropic hypogonadism 13 with or without anosmia is inherited; in many families it is, but it can also occur without a known family history. The condition stems from a change in a specific gene that disrupts the brain hormone signals that trigger puberty and, in some people, the wiring for the sense of smell—so loss of smell may or may not be present. These gene changes may be passed down within a family or arise as a new change that wasn’t present in either parent, and different relatives can be affected to different degrees. Having a gene change doesn’t always mean you will develop the condition. One person may have very delayed or absent puberty, while a sibling with the same change has milder hormone issues or normal smell. Genetic testing and counseling can often identify the gene involved and help estimate the chance of passing it on to future children.
Is Hypogonadotropic hypogonadism 13 with or without anosmia genetic?
Genetics play a central role in hypogonadotropic hypogonadism 13 with or without anosmia. Variants in the CHD7 gene commonly cause it, and inheritance is usually autosomal dominant, sometimes de novo. Testing helps confirm diagnosis, guide family planning, and inform counseling.
Pharmacogenetics—how genetics influence drug effects
For Hypogonadotropic hypogonadism 13 with or without anosmia, the specific genetic change can influence which hormone treatment is most likely to help. When the issue is a weak signal from the brain, tiny pulses of gonadotropin-releasing hormone (GnRH) delivered by a small pump can “switch on” the downstream glands; if the body’s GnRH receptor doesn’t respond well, giving the next-step hormones directly (human chorionic gonadotropin and follicle-stimulating hormone) is usually the better route. Genetic results may also hint at who is more likely to experience a later “reversal” of hormone function, which can guide how often doctors reassess and whether a supervised trial off therapy makes sense. For testosterone or estrogen–progesterone replacement, inherited differences in how the body processes hormones can change how quickly a dose is cleared or how strong it feels, so some people need a different form or amount to reach the same effect. Not every difference in response is genetic, but factors like age, body size, liver health, and whether a medicine is a patch, pill, or injection also play a role. In practice, doctors combine genetic findings with lab results and treatment goals (such as inducing puberty or planning pregnancy) to choose between GnRH therapy, gonadotropin injections, or sex-steroid replacement and to fine-tune dosing over time. Starting care soon after early symptoms of Hypogonadotropic hypogonadism 13 with or without anosmia are noticed can help protect bone strength and support future fertility planning, while the genetics help personalize the path.
Interactions with other conditions
Living with hypogonadotropic hypogonadism 13 with or without anosmia can intersect with other health issues in ways that affect day-to-day life, especially bone, metabolic, and mental health. Low sex hormone levels raise the risk of low bone density and fractures over time; if someone also has vitamin D deficiency, a history of long‑term steroid use, or limited weight‑bearing activity, bone loss can be more pronounced. Doctors call it a “comorbidity” when two conditions occur together, and common ones to consider here include thyroid problems, high prolactin levels, type 2 diabetes, and sleep apnea, which can blur the picture or add to fatigue, low libido, and mood changes. Because early symptoms of hypogonadotropic hypogonadism 13 can resemble thyroid disease or depression, careful testing helps separate what’s due to hormone deficiency from what’s caused by another condition.
Treatment can interact with other illnesses, too. Testosterone or estrogen therapy can improve energy, mood, and bone health, but may worsen untreated sleep apnea and needs extra caution in people with clotting disorders, migraines with aura, or certain heart risks. If anosmia is present, chronic sinus or allergy symptoms won’t cause it, but they can further dull smell and taste, adding practical safety concerns at home. Talk with your doctor about how your conditions may influence each other, so your plan covers hormones, bone protection (calcium, vitamin D, exercise), and screening for metabolic and mental health needs.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described delayed puberty and absent smell in certain family lines, long before hormones or genes were understood. A teenager staying shorter, with no voice change or periods, while younger siblings develop normally, was often noted in school physicals or sports exams. In some relatives, the same pattern repeated across generations, sometimes with no sense of smell from childhood.
First described in the medical literature as a form of isolated hypogonadotropic hypogonadism and later linked with absent smell (anosmia) in many, this condition gradually took shape as a recognizable syndrome. Early reports focused on outward features—late or absent puberty—because those were easiest to see. As hormone testing became available in the mid-20th century, clinicians could measure low levels of the brain signals that normally trigger the ovaries or testes, confirming the “central” origin. With each decade, careful case reports expanded the picture to include normal or reduced sense of smell, small reproductive organs unless treated, and in some families, varied severity among siblings.
Advances in genetics shifted the story again. Researchers began finding rare changes in genes that guide the development and movement of the brain cells that release puberty-starting hormones. In some families with hypogonadotropic hypogonadism, these same pathways also affected the wiring needed for smell, explaining why anosmia appears in many but not all. Hypogonadotropic hypogonadism 13 with or without anosmia emerged from this work as one of several numbered genetic forms, defined by a specific gene change and a shared pattern of delayed or absent puberty—with smell either missing or preserved.
From early theories to modern research, the story of Hypogonadotropic hypogonadism 13 with or without anosmia reflects how diagnoses evolve as tools improve. What once seemed like a single, rare disorder is now recognized as a group of related conditions with overlapping features. Not every early description was complete, yet together they built the foundation of today’s knowledge. Modern studies use detailed hormone testing and targeted genetic panels to identify the cause, which helps guide care and informs family planning. Even so, history reminds us that there is real variability—two people in the same family can have different ages of symptom onset, different smell abilities, and different responses to treatment—so care remains personalized.